The incorporation of biomarker-guided patient selection into GM-CSF-targeted therapeutic strategies holds the potential to transform RA management from empirically derived, population-based interventions toward a precision medicine paradigm [10]. The gene discussed is CSF2; the disease is rheumatoid arthritis.